Paul Scorer is Principal Scientist Histology at Oncologica
Paul joined Oncologica® in March 2021 as Principal Scientist in Histology. He is responsible for delivering histology and immunocytochemistry (ICC) testing, part of Oncologica®’s clinical oncology genetic sequencing service offered to cancer patients. Paul also has a role in co-ordinating research focused on correlation of Oncologica® sequencing results and patient response and the development of diagnostic tests linked to therapeutic intervention strategies.
Paul has over 40 years experience in all aspects of clinical histology/ICC, diagnostics testing, pharmaceutical development, project leading and quality control. Paul began his career in histopathology at the Queen Elizabeth Hospital in Gateshead where he spent 25 years, including 18 years as senior BMS running the ICC service. Paul moved to private industry joining Vision Biosystems (Novocastra Laboratories) in Newcastle (subsequently Leica Biosystems) spending 12 years in QC, R&D and clinical assay development. In 2015 Paul joined the pharmaceutical company AstraZeneca in Cambridge, spending 6 years as Associate Principal Scientist in Precision Medicine mainly focused on drug therapies and ICC assays targeting PD-L1 expression in tumours.
Paul is an Executive Board Member of UK NEQAS CPT, an EQA assessor and responsible for annually delivering histology specialist staining techniques and ICC educational lectures/workshops for UKNEQAS CPT.
Published Research Papers
Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer
J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33664-0. doi: https://doi.org/10.1016/j.jtho.2019.11.010.
Williams GH, Nicholson AG, Snead DRJ, Thunnissen E, Lantuejoul S, Cane P, Kerr KM, Loddo M, Scott MLJ, Scorer PW, Barker C. (2019)
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
David Jonathan Duncan ,Marietta Scott,Paul Scorer et al ()
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
Mod Pathol. 2019 Sep 26. doi: https://doi.org/10.1038/s41379-019-0372-z. [Epub ahead of print] Erratum in: Mod Pathol. 2019 Oct
Lawson NL, Dix CI, Scorer PW, Stubbs CJ, Wong E, Hutchinson L, McCall EJ, Schimpl M, DeVries E, Walker J, Williams GH, Hunt J, Barker C. (2019)
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
Diagnostic Pathology, (2018) 13:47 DOI: https://doi.org/10.1186/s13000-018-0725-9
Paul Scorer, Marietta Scott, Nicola Lawson et al (2018)
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cut-Offs in Non-Small Cell Lung Cancer
Clinical Cancer Research, January 2017; 16-2375 DOI: https://doi.org/10.1158/1078-0432.ccr-16-2375
Marianne J Ratcliffe, Alan Sharpe, Anita Midha et al (2017)
Nature – Scientific Reports, April 2017, 7, 45938 DOI: https://doi.org/10.1038/srep45938
Michel E. Vandenberghe, Marietta L. J. Scott, Paul W. Scorer et al (2017)